GSK recalls 600,000 Ventolin Inhalers from US
Multinational pharmaceutical company, GlaxoSmithKline (GSK) has announced the recall of over 590,000 Salbutamol (Ventolin) inhalers from the US market, saying there could be issues with the delivery technique.
The recall is for three lots of Ventolin HFA 200D inhalers with lot numbers 6ZP0003, 6ZP9944 and 6ZP9848.
The inhalers, according to reports, have been distributed to hospitals, pharmacies, retailers and wholesalers in the United States.
“There is attainable risk that the affected inhalers could potentially not deliver the stated number of actuations,” according to GSK spokesman Juan Carlos Molina. “We continue to investigate the situation in order to identify the root lead to and implement appropriate corrective and preventative actions.”
The recall is not directed at individuals, but those with inhalers from the recalled lots have been advised to contact the company.
About author
You might also like
Accomplished journalist, PR Specialist, Abubakar Jimoh bows out of NAFDAC
After 30 years of meritorious service Astute Journalist, Consummate Public Relations Practitioner and Director of Public Affairs of the National Agency for Food and Drug Administration and Control (NAFDAC), Dr.
Pharma company recommends Free Malaria Management programme as part of fuel subsidy palliative
As Nigeria joins the rest of the world to mark the World Malaria Day today, a leading pharmaceutical company, St. Racheal’s Pharma, has called on the in-coming administration led by
Analgesics and your kidney: Facts to know
Many analgesics should not be used if there is decreased kidney function, because they reduce the blood flow to the kidney. Also,
0 Comments
No Comments Yet!
You can be first to comment this post!